Р.Отгонбаяр
Loading...
Товч нэр
Р.Отгонбаяр
Бүтэн нэр
Раднаа Отгонбаяр
Латин нэр
Radnaa Otgonbayar
Албан тушаал
Багш
Харьяалал
ORCID
2 results
Now showing 1 - 2 of 2
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Changes in mental health following COVID-19 infection: Results of a prospective cohort study in Mongolia(Mongolian National University of Medical Sciences, 2026-03-30) ;aa Enkhtuvshin Regzed ;Mongoljin Altankhuyag; ; Yelik MadiObjective: COVID-19 has been associated with persistent neuropsychiatric complications, yet prospective evidence from low- and middle-income countries remains limited. This study evaluated 12-month longitudinal changes in depression, anxiety, insomnia, and post-traumatic stress disorder (PTSD) among hospitalized patients with COVID-19 compared with non-COVID-19 controls in Mongolia. Methods: This prospective cohort study included 459 adults (326 COVID-19 cases and 133 controls) recruited from hospitals affiliated with the Mongolian National University of Medical Sciences between 2021 and 2023. Participants without baseline mental disorders were assessed at 7–14 days, 3 months, and 12 months using the PHQ-9, GAD-7, ISI, and PCL-5. Data were analyzed using X² tests, independent t-tests, and relative risk (RR) estimates, with statistical significance defined as p < 0.05. Results: The mean age of participants was 46.3 ± 13.8 years, and 58.4% were female. At 12 months, depression (37.3% vs. 16.9%; RR = 2.22, 95% CI: 1.28–3.83; p = 0.003) and anxiety (28.0% vs. 11.2%; RR = 2.49, 95% CI: 1.25–4.96; p = 0.006) remained significantly more common in the COVID-19 group than in controls. Insomnia decreased over time (33.3% vs. 49.4%; RR = 0.67; p = 0.037), whereas PTSD prevalence remained low in both groups (<3%, p > 0.05). Female participants and those aged 40–59 years showed a higher risk of adverse mental health outcomes. Conclusions: COVID-19 infection was associated with a significantly increased long-term risk of depression and anxiety up to 12 months after infection. These findings support routine mental health screening and sustained psychological follow-up as part of post-COVID care and provide evidence to inform long-term mental health policy in Mongolia. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study(The Korean Association for the Study of the Liver, 2021-01); ;Lee, Jae Seung ;Amarsanaa, Jazag; Ahn, Sang HoonBACKGROUND/AIMS: Ledipasvir/sofosbuvir (LDV/SOF) shows high efficacy and safety in patients with genotype 1-hepatitis C virus (HCV). We aimed to investigate the efficacy and safety of LDV/SOF in real-world Mongolian patients. METHODS: Between 2015 to 2019, 23 (0.5%) and 5,005 patients (99.5%) with genotype 1a and 1b HCV, respectively, were treated with a fixed-dose tablet containing 90 mg ledipasvir and 400 mg sofosbuvir for 12 weeks, and 81 patients (1.6%) with previous experience of interferon (IFN)-based treatment received additional 1,000 mg ribavirin. HCV RNA was measured at 4, 12, and 24 weeks after the first dose to determine rapid virologic response, end of treatment response (ETR), and sustained virologic response at 12 weeks after end of treatment (SVR12). RESULTS: Most patients (n=5,008; 99.6%) achieved ETR and SVR12 without virologic relapse. Patients with genotype 1a showed low rates of ETR and SVR12 in only 16 patients (69.6%). There was no significant difference in SVR12 rate between patients regardless of IFN experience (n=81; 1.6%), cirrhosis (n=1,151; 22.9%), HCV RNA >6×106 IU/mL (n=866; 17.2%), or liver stiffness >9.6 kPa (n=1,721; 34.2%) (100.0%, 99.3%, 99.4%, and 99.4%, respectively). No severe adverse events (AEs) were reported, and there was no dose reduction or interruption due to AE. The most common AEs were headache (n=472; 9.4%), fatigue (n=306; 6.2%), abdominal discomfort (n=295; 5.9%), and skin rash (n=141; 2.8%). CONCLUSION: LDV/SOF showed high efficacy and safety for patients with genotype 1, especially 1b HCV, in Mongolia. The real-world data might be applicable to patients in other Asian-Pacific countries.Scopus© Citations 5
